Home › Funds › STEMPOINT CAPITAL LP › KNSA
STEMPOINT CAPITAL LP position in KNSA
KINIKSA PHARMACEUTICALS INTL · Health Care
STEMPOINT CAPITAL LP reported holding 209,234 shares of KNSA (KINIKSA PHARMACEUTICALS INTL) in its Q2 2026 13F filing — a position valued at US$13.4M, representing 2.96% of its reported portfolio and ranking #7 among its reported holdings. STEMPOINT CAPITAL LP has disclosed KNSA holdings in 2 of the last 11 reported quarters, going back to Q4 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How STEMPOINT CAPITAL LP's KNSA position evolved
STEMPOINT CAPITAL LP first disclosed a stake in KNSA in Q4 2023 at 183,102 shares (US$3.2M). The position peaked in Q2 2026 at 209,234 shares, worth US$13.4M. Across 2 filings, STEMPOINT CAPITAL LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 209,234 shares valued at US$13.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2023 | 183.10K | $3.21M | New |
| Q2 2026 | 209.23K | $13.38M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KNSA and 13F data
KNSA (KINIKSA PHARMACEUTICALS INTL) is a Health Care company. 48 other funds we track also report a position in KNSA — the largest reported positions include Rubric Capital Management LP (US$255.8M), BAKER BROS. ADVISORS LP (US$181.3M), TANG CAPITAL MANAGEMENT LLC (US$144.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KNSA
- Rubric Capital Management LP 4.00M sh · $255.79M · Q2 2026
- BAKER BROS. ADVISORS LP 2.83M sh · $181.28M · Q2 2026
- TANG CAPITAL MANAGEMENT LLC 2.26M sh · $144.52M · Q2 2026
- Spruce Street Capital LP 918.07K sh · $58.71M · Q2 2026
- RICE HALL JAMES & ASSOCIATES, LLC 624.93K sh · $39.96M · Q2 2026
- ORBIMED ADVISORS LLC 420.60K sh · $26.90M · Q2 2026
- Penn Capital Management Company, LLC 368.11K sh · $23.57M · Q2 2026
- Soleus Capital Management, L.P. 246.35K sh · $15.75M · Q2 2026
- ESSEX INVESTMENT MANAGEMENT CO LLC 202.02K sh · $15.07M · Q3 2026
- ArrowMark Colorado Holdings LLC 215.55K sh · $13.78M · Q2 2026
More on STEMPOINT CAPITAL LP
FAQ
How long has STEMPOINT CAPITAL LP held KNSA?
STEMPOINT CAPITAL LP has disclosed KNSA holdings in 2 of the last 11 reported quarters, going back to Q4 2023.
What is STEMPOINT CAPITAL LP's current position in KNSA?
As of Q2 2026, STEMPOINT CAPITAL LP holds 209.23K shares of KNSA (KINIKSA PHARMACEUTICALS INTL), valued at $13.38M, representing 2.96% of its reported portfolio and ranking #7.
Has STEMPOINT CAPITAL LP been buying or selling KNSA?
In the latest 13F filing (Q2 2026), STEMPOINT CAPITAL LP newly opened its position in KNSA. The position peaked in Q2 2026 at 209.23K shares.
Which other funds hold KNSA?
Other major institutional holders of KNSA include Rubric Capital Management LP, BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, among 48 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.